TheEdgeResearch
Home / Stocks / INCR

InterCure Ltd. (INCR)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$0.97 ▲ +1.21%
Market Cap
$57.5M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.57
52-Wk Range
0.68-1.71
CEO
Alexander Rabinovich
Country
IL
Currency
USD

InterCure Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Herzliya, TA, IL. The stock last traded at $0.97, up 1.21% on the session, giving a market capitalisation of $57.5M. On trailing twelve-month figures it carries a trailing P/E of -3.97, a net margin of -13.2%. Its beta of 0.57 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.97
Price / Sales
0.62
Price / Book
0.36
EV / EBITDA
-5.49
Gross margin
15.1%
Operating margin
-10.1%
Net margin
-13.2%
Return on equity
Debt / equity
0.46
Current ratio
1.48
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
285
IPO date
2019-01-28
Headquarters
Herzliya, TA, IL
About InterCure Ltd.

InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.

Comparable companies

InterCure Ltd. is most often compared with the following Healthcare names:

AMWLASRTBMEACAMPCRDLEDAPFBIOHYFTRPTXUNCY
More research on INCR
INCR technical analysis INCR TheEdge Score Compare against peers
Open full interactive analysis & DCF →